Vinblastine and methotrexate for advanced bladder cancer

Area of Science:

• Oncology
• Urothelial Tract Cancer Treatment
• Chemotherapy Regimens

Background:

• Advanced urothelial tract cancer presents significant treatment challenges.
• Effective and tolerable outpatient regimens are needed for managing this disease.

Purpose of the Study:

• To evaluate the efficacy and tolerability of a weekly combination regimen of vinblastine and methotrexate in patients with advanced urothelial tract cancer.
• To assess remission rates, duration of response, and survival outcomes in treated patients.

Main Methods:

• A cohort of 57 patients with advanced measurable urothelial tract cancer was treated weekly with vinblastine and methotrexate.
• Treatment involved 3-4 mg/m² vinblastine and 30-40 mg/m² methotrexate.
• Response was assessed based on unidimensional and bidimensional parameters, including remission rates and duration.

Main Results:

• Of 47 patients with bidimensionally measurable disease, 19 (40%) achieved complete or partial remission, with a median duration of 8 months.
• Patients who had not received prior chemotherapy showed a higher remission rate (18/38) compared to those previously treated (1/9).
• Responders demonstrated significantly longer survival (14 months vs. 8 months for non-responders) and were more likely to achieve subsequent remissions.

Conclusions:

• The combination of weekly vinblastine and methotrexate is a well-tolerated and effective outpatient regimen for advanced urothelial tract cancer.
• This regimen offers significant benefits in terms of remission rates and improved survival, especially for chemotherapy-naive patients.
• Further investigation into this combination therapy for urothelial cancers is warranted.